GlassScriptPhysician profile
Jacob A Bishop
NPI 1013324136
$56,420.32
in general payments reported to CMS, 2019-2025
14 companies · $55K in 2025
The $55K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $70.37 · 2021: $128 · 2022: $444 · 2023: $556 · 2024: $378 · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Consulting Fee: $6,310 · Travel and Lodging: $3,245 · Food and Beverage: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,920.00 |
| Consulting Fee | $6,310.00 |
| Travel and Lodging | $3,244.79 |
| Food and Beverage | $2,145.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $55,218.59 | 2019-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $488.03 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Otsuka America Pharmaceutical, INC. | $181.46 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $115.79 | 2021-2025 | Sublocade, Perseris |
| Lundbeck LLC | $83.86 | 2023-2024 | Abilify Maintena |
| Bioxcel Therapeutics, INC. | $58.83 | 2023 | Igalmi |
| E.R. Squibb & Sons, L.L.C. | $57.38 | 2025 | Cobenfy |
| Abbvie INC. | $52.00 | 2023-2025 | Vraylar |
| Ironshore Pharmaceuticals INC. | $46.15 | 2024 | |
| Axsome Therapeutics, INC. | $37.16 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $30.42 | 2022-2023 | Austedo |
| Neurocrine Biosciences, INC. | $18.75 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.61 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.29 | 2024 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.